title: Use of an amphotericin B lipid complex for treatment of blastomycosis in dogs.
abstract: OBJECTIVE
  To evaluate efficacy and nephrotoxicity of amphotericin B lipid complex used for treatment of dogs with naturally developing blastomycosis.
  
  
  METHODS
  Prospective clinical trial.
  
  
  METHODS
  11 dogs with blastomycosis.
  
  
  METHODS
  All dogs were treated with an amphotericin B lipid complex. Two dogs received a cumulative dose of 8 mg/kg of body weight, 1 received a cumulative dose of 10 mg/kg, and 8 received a cumulative dose of 12 mg/kg.
  
  
  RESULTS
  The 2 dogs that received a cumulative dose of 8 mg/kg and 1 of the dogs that received a cumulative dose of 12 mg/kg had a relapse of blastomycosis within 30 days after treatment. Seven of the remaining 8 dogs were clinically free of blastomycosis 6 months after treatment. One dog died of an unrelated cause 5.5 months after treatment, but did not have clinical signs of blastomycosis at the time of death. There were not any adverse clinical effects attributable to drug administration in any of the dogs in this study, and none of the dogs developed clinical signs of renal disease or failure.
  
  
  CONCLUSIONS
  Amphotericin B lipid complex was a safe and effective treatment for blastomycosis in these dogs.
authors.affiliation: Department of Veterinary Clinical Medicine, College of Veterinary Medicine, University of Illinois, Urbana 61801, USA.
authors.forename: D R
authors.initials: DR
authors.lastname: Krawiec
authors.forename: B C
authors.initials: BC
authors.lastname: McKiernan
authors.forename: A R
authors.initials: AR
authors.lastname: Twardock
authors.forename: C E
authors.initials: CE
authors.lastname: Swenson
authors.forename: R J
authors.initials: RJ
authors.lastname: Itkin
authors.forename: L R
authors.initials: LR
authors.lastname: Johnson
authors.forename: L K
authors.initials: LK
authors.lastname: Kurowsky
authors.forename: C A
authors.initials: CA
authors.lastname: Marks
mesh_terms: D000666:Amphotericin B / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000818:Animals; D000935:Antifungal Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001759:Blastomycosis / Q000188:drug therapy / Q000662:veterinary*; D004283:Dog Diseases / Q000188:drug therapy*; D004285:Dogs; D004337:Drug Carriers; D004338:Drug Combinations; D005260:Female; D005919:Glomerular Filtration Rate / Q000187:drug effects / Q000662:veterinary; D007668:Kidney / Q000187:drug effects; D008081:Liposomes; D008297:Male; D010713:Phosphatidylcholines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D010715:Phosphatidylglycerols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D011446:Prospective Studies; D016896:Treatment Outcome
chemical_list: D000935:Antifungal Agents; D004337:Drug Carriers; D004338:Drug Combinations; D008081:Liposomes; D010713:Phosphatidylcholines; D010715:Phosphatidylglycerols; C068538:liposomal amphotericin B; D000666:Amphotericin B